Dr. Monk on Potential Shifts to Treatment Sequencing Strategies in Cervical Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.
Dr. Monk on the Utility of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.
Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.
Managing AEs With Pembrolizumab and Lenvatinib
Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.
Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer
Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.
A Discussion on the Study 309/KEYNOTE-775 Data
Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.
Results from Study 309/KEYNOTE-775
Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.
Dr. Monk on Guidelines for Maintenance PARP Inhibitors in Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.
Study 309/KEYNOTE-775 Trial Design
Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.
Therapeutic Approaches in Endometrial Cancer
Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.
Dr. Monk on the Clinical Implications of the PRIMA Trial in Advanced Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the clinical implications of the phase 3 PRIMA trial in newly diagnosed advanced ovarian cancer.
Future of Advanced Endometrial Cancer
Novel Targets for Advanced Endometrial Cancer
Endometrial Cancer: Chemo-Free Regimens on the Horizon
Emerging Agents: Treatment of Endometrial Cancer
Sequencing for Advanced Endometrial Cancer
Recurrent Endometrial Cancer: Safety of Combination Therapy
Combination Therapy for Recurrent Endometrial Cancer
Emerging ICI Therapy for Advanced Endometrial Cancer
Immune Checkpoint Inhibitors in Advanced Endometrial Cancer
GOG-258 and PORTEC-3 Studies in Endometrial Cancer
GOG-249 Study in Early-Stage Endometrial Cancer
GOG 0209 Study in Advanced Endometrial Cancer
Role of Biomarker Testing in Endometrial Cancer
Risk Classification of Endometrial Cancer
Overview of Endometrial Cancer
Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial
Dr. Monk on Emerging Therapies in Cervical Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.
Dr. Monk on the Importance of Early Pap Testing in Cervical Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the importance of Pap testing early on in cervical cancer.
Dr. Monk on the Limitations of Current Treatment in Metastatic/Recurrent Cervical Cancer
Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.
Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities
Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors
Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer
Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer
2 Clarke Drive Cranbury, NJ 08512